Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MK-7009 with peginterferon alfa-2a and ribavirin in treatment-naive genotype 1 chronic hepatitis C
2009-012000-10Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vaniprevir in hepatitis C virus infection (6 arms), sponsored by Merck & Co. Primary endpoint: Sustained virologic response at 24 weeks. Started May 2009; status: terminated.
02
Drugs
vaniprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-012000-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012000-10.